Zhou Y, Xu T, Zhou Y, Han W, Wu Z, Yang C
Front Immunol. 2024; 15():1436031.
PMID: 39650659
PMC: 11621000.
DOI: 10.3389/fimmu.2024.1436031.
Leng D, Zeng B, Wang T, Chen B, Li D, Li Z
Zool Res. 2024; 45(5):1088-1107.
PMID: 39245652
PMC: 11491784.
DOI: 10.24272/j.issn.2095-8137.2024.037.
Ye J, Wei B, Zhou G, Xu Y, He Y, Hu X
Cell Oncol (Dordr). 2024; 47(4):1333-1353.
PMID: 38502270
PMC: 11322377.
DOI: 10.1007/s13402-024-00930-0.
Wang J, Li J, Kramer S, Su L, Chang Y, Xu C
Nat Commun. 2023; 14(1):7367.
PMID: 37963892
PMC: 10645821.
DOI: 10.1038/s41467-023-43256-5.
Thomas R, Yang X
Curr Res Immunol. 2023; 4:100060.
PMID: 37645659
PMC: 10461194.
DOI: 10.1016/j.crimmu.2023.100060.
Organization of the human intestine at single-cell resolution.
Hickey J, Becker W, Nevins S, Horning A, Perez A, Zhu C
Nature. 2023; 619(7970):572-584.
PMID: 37468586
PMC: 10356619.
DOI: 10.1038/s41586-023-05915-x.
Adult expression of Semaphorins and Plexins is essential for motor neuron survival.
Vaikakkara Chithran A, Allan D, OConnor T
Sci Rep. 2023; 13(1):5894.
PMID: 37041188
PMC: 10090137.
DOI: 10.1038/s41598-023-32943-4.
Dimension-agnostic and granularity-based spatially variable gene identification.
Wang J, Li J, Kramer S, Su L, Chang Y, Xu C
bioRxiv. 2023; .
PMID: 36993544
PMC: 10055351.
DOI: 10.1101/2023.03.21.533713.
Dimension-agnostic and granularity-based spatially variable gene identification.
Wang J, Li J, Kramer S, Su L, Chang Y, Xu C
Res Sq. 2023; .
PMID: 36993309
PMC: 10055640.
DOI: 10.21203/rs.3.rs-2687726/v1.
Sema4C Is Required for Vascular and Primary Motor Neuronal Patterning in Zebrafish.
Sheng J, Jiang B, Shi R, Shi L, Liu D
Cells. 2022; 11(16).
PMID: 36010604
PMC: 9406964.
DOI: 10.3390/cells11162527.
Semaphorins as Potential Immune Therapeutic Targets for Cancer.
Jiang J, Zhang F, Wan Y, Fang K, Yan Z, Ren X
Front Oncol. 2022; 12:793805.
PMID: 35155237
PMC: 8830438.
DOI: 10.3389/fonc.2022.793805.
Development and Validation of a Combined Glycolysis and Immune Prognostic Model for Melanoma.
Yang Y, Li Y, Qi R, Zhang L
Front Immunol. 2021; 12:711145.
PMID: 34659201
PMC: 8517401.
DOI: 10.3389/fimmu.2021.711145.
Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile.
Younis R, Ghita I, Elnaggar M, Chaisuparat R, Theofilou V, Dyalram D
Front Immunol. 2021; 12:596646.
PMID: 33776991
PMC: 7991916.
DOI: 10.3389/fimmu.2021.596646.
Semaphorin 4D is a potential biomarker in pediatric leukemia and promotes leukemogenesis by activating PI3K/AKT and ERK signaling pathways.
Jiang H, Tang J, Qiu L, Zhang Z, Shi S, Xue L
Oncol Rep. 2021; 45(4).
PMID: 33649851
PMC: 7877000.
DOI: 10.3892/or.2021.7952.
The nAChR Chaperone TMEM35a (NACHO) Contributes to the Development of Hyperalgesia in Mice.
Khasabov S, Rogness V, Beeson M, Vulchanova L, Yuan L, Simone D
Neuroscience. 2021; 457:74-87.
PMID: 33422618
PMC: 7897319.
DOI: 10.1016/j.neuroscience.2020.12.027.
Insufficient CD100 shedding contributes to suppression of CD8 T-cell activity in non-small cell lung cancer.
Wang H, Zhang X, Ye L, Zhang K, Yang N, Geng S
Immunology. 2020; 160(2):209-219.
PMID: 32149403
PMC: 7218665.
DOI: 10.1111/imm.13189.
Semaphorin 5A suppresses the proliferation and migration of lung adenocarcinoma cells.
Ko P, Lenka G, Chen Y, Chuang E, Tsai M, Sher Y
Int J Oncol. 2019; 56(1):165-177.
PMID: 31789397
PMC: 6910195.
DOI: 10.3892/ijo.2019.4932.
Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents.
Zuazo-Gaztelu I, Paez-Ribes M, Carrasco P, Martin L, Soler A, Martinez-Lozano M
Cancer Res. 2019; 79(20):5328-5341.
PMID: 31239269
PMC: 7611261.
DOI: 10.1158/0008-5472.CAN-18-3436.
Association between prognosis and SEMA4D/Plexin-B1 expression in various malignancies: A meta-analysis.
Yang Y, Wang J, Li H, Liu L, Yao M, Xiao T
Medicine (Baltimore). 2019; 98(7):e13298.
PMID: 30762724
PMC: 6407964.
DOI: 10.1097/MD.0000000000013298.
Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
Clavijo P, Friedman J, Robbins Y, Moore E, Smith E, Zauderer M
Cancer Immunol Res. 2018; 7(2):282-291.
PMID: 30514791
PMC: 8326929.
DOI: 10.1158/2326-6066.CIR-18-0156.